Monday, May 16, 2022
name of Prensa Latina
Bandera inglesa
English Edition
name of Prensa Latina

NEWS

NEWS

Cuban president reviews Covid-19 control, Jusvinza drug effectiveness

Cuban president reviews Covid-19 control, Jusvinza drug effectiveness

Havana, Feb 8 (Prensa Latina) Cuban President Miguel Díaz-Canel and local scientists on Tuesday ratified that the Covid-19 infection forecasts are quite favorable for all provinces, so the epidemic remains under control.
Share on facebook
Share on twitter
Share on whatsapp
Share on telegram
Share on email

According to the Presidency´ official Twitter account, the meeting also assessed the encouraging outcomes of the clinical studies of Jusvinza drug for treating rheumatoid arthritis, a disease that is currently affecting more than 136,000 Cubans.

The new drug -produced by the Cuban Center for Genetic Engineering and Biotechnology (CIGB, in Spanish)- has also shown high effectiveness in Covid-19 patients.

Jusvinza is the first therapeutic product in Cuba based on synthetic peptide. It improves ventilatory parameters and inflammation markers, which leads to the recovery of Covid-19 people.

In a similar meeting last October, DSc. María del Carmen Domínguez presented the Jusvinza (CIGB-258) results, which have allowed high levels of recovery of seriously-ill patients.

The same positive effects were achieved with the application to pregnant women (to reduce extremely serious maternal morbidity and maternal mortality), she reported.

Jusvinza could be used to treat rheumatoid arthritis, juvenile idiopathic arthritis, which affects children, and sepsis, specifically community-acquired pneumonia.

mh/pll/ode/idm

RELATED
ÚLTIMO MINUTO
name of Prensa Latina

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

© 2016-2021 Prensa Latina
Latin American News Agency

Radio – Publications  – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado,  Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division  Prensa Latina.